NPR ran an updated story on the ‘battle’ between compounders and drug makers over GLP-1 weight-loss...
A quick quote from Scott in WaPo
The Washington Post’s story “Eli Lilly ramps up its fight against imitation weight-loss drugs” contains a short quote from CEO Scott Brunner. He’s responding to Lilly’s contention (an incorrect one, at that) that compounded GLP-1 drugs are “non-sterile products.”
As Scott pointed out, “[C]ompounded weight-loss drugs that are injectable, like tirzepatide, ‘can only be prepared in sterile compounding labs’.”
